{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:13:01Z","timestamp":1788300781605,"version":"build-2803163510"},"reference-count":37,"publisher":"Korean Diabetes Association","issue":"1","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008130","name":"Pusan National University Hospital","doi-asserted-by":"publisher","award":["20220025"],"award-info":[{"award-number":["20220025"]}],"id":[{"id":"10.13039\/501100008130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["e-dmj.org"],"crossmark-restriction":true},"short-container-title":["Diabetes Metab J"],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:p>Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for the treatment of type 2 diabetes mellitus (T2DM) given their extra-pancreatic effects. However, there are concerns about carcinogenesis in the pancreas and thyroid gland. We aimed to evaluate the site-specific incidence of cancer in patients with T2DM-treated GLP-1 RAs using a nationwide cohort.Methods: This study included data obtained from the Korean National Health Insurance Service (between 2004 and 2021). The primary outcome was newly diagnosed cancer, and the median follow-up duration for all participants was 8 years.Results: After propensity score matching, 7,827 participants were analyzed; 2,609 individuals each were included in the GLP-1 RA, diabetes mellitus (DM) control, and non-DM control groups. The incidence rate ratio (IRR) of subsequent cancer in patients with T2DM was 1.73, which was higher than that of individuals without DM, and it increased in both men and women. Analysis of patients with T2DM showed no increased cancer risk associated with the use of GLP-1 RA, and similar results were observed in both men and women. The IRRs of pancreatic cancer (0.74), thyroid cancer (1.32), and medullary thyroid cancer (0.34) did not significantly increase in the GLP-1 RA group compared with those in the DM control group.Conclusion: There was a 73% higher risk of cancer in patients with T2DM compared with the general population. However, among patients with T2DM, there was no association between the use of GLP-1 RAs and new-onset cancers, including pancreatic and medullary thyroid cancers.<\/jats:p>","DOI":"10.4093\/dmj.2024.0105","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T01:57:06Z","timestamp":1729735026000},"page":"49-59","update-policy":"https:\/\/doi.org\/10.4093\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Use of Glucagon-Like Peptide-1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients with Type 2 Diabetes Mellitus"],"prefix":"10.4093","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1538-8859","authenticated-orcid":true,"given":"Mijin","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Chan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9632-9457","authenticated-orcid":true,"given":"Bo Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2567","reference":[{"key":"ref1","volume-title":"","year":"2021"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05585-2"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/1474651413495703"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7607"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.04.002"},{"key":"ref6","first-page":"S158","volume-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024","year":"2024"},{"key":"ref7","first-page":"575","volume-title":"2023 Clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association","author":"Choi","year":"2023"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.31068"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2337\/db11-1838"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.02.018"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-1272"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2012.07.024"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-10-20"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1825"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2012.09.008"},{"key":"ref16","first-page":"799","volume-title":"Data resource profile: the National Health Information Database of the National Health Insurance Service in South Korea","author":"Seong","year":"2017"},{"key":"ref17","first-page":"121","volume-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","author":"Gerstein","year":"2019"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1603827"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.15430\/jcp.2018.23.4.183"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3803\/enm.2020.709"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2014.110"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2020.1798099"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.08.088"},{"key":"ref24","first-page":"1233","volume-title":"Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials","author":"Monami","year":"2017"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-38956-2"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1210\/en.2010-0115"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0883"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1753-0407.2010.00079.x"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1530\/ec-17-0294"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2174\/1567201816666191010145029"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103242"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23951"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1210\/en.2017-00461"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2337\/db13-1169"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1530\/jme-19-0186"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1996"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2019.0177"}],"container-title":["Diabetes &amp; Metabolism Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-dmj.org\/upload\/pdf\/dmj-2024-0105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-dmj.org\/journal\/view.php?doi=10.4093\/dmj.2024.0105","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-dmj.org\/upload\/pdf\/dmj-2024-0105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T05:59:58Z","timestamp":1736920798000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-dmj.org\/journal\/view.php?doi=10.4093\/dmj.2024.0105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"URL":"https:\/\/doi.org\/10.4093\/dmj.2024.0105","relation":{},"ISSN":["2233-6079","2233-6087"],"issn-type":[{"value":"2233-6079","type":"print"},{"value":"2233-6087","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,1]]},"assertion":[{"value":"2024-03-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-24","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-01","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}